Epstein–Barr virus (EBV)

November 15, 2019

Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection

News

The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas ... Read more

May 30, 2018

Atara’s Tab-cel Shows Promise for Treating Transplant-derived Lymphoma, Trial Data Shows

News

Atara Biotherapeutics’s investigative therapy Tab-cel (tabelecleucel) is a potentially safe and viable option to treat transplant-derived lymphoma, according to long-term data from two Phase 2 clinical trials. The new results will ... Read more

November 18, 2016

Epstein-Barr Virus Promotes Lymphoma by Taking Control of 2 Key Genes, Study Finds

News

Epstein-Barr virus, which causes mononucleosis, can also cause lymphoma by taking control of two genes involved in blood cancers and switching them on or off, a new study reported. The study, “MYC activation and ... Read more

August 5, 2016August 23, 2016

Study Identifies Killer T-cells That Destroy Viral Infections Linked to Lymphoma

News

Researchers may be one step closer to curing chronic viral infections, such as those caused by HIV and Epstein-Barr virus (EBV), an achievement that would directly affect incidences of lymphoma, since both ... Read more

December 1, 2015December 1, 2015

Combo Therapy May Ease Lymphoma Risk in Young Organ Transplant Patients

News

A combination immunosuppressive therapy of cyclosporin A with everolimus may be an effective treatment for pediatric patients undergoing to organ transplants. These are the results of a study recently published in the journal International ... Read more